Printer Friendly

IMMUNEX SEPSIS DRUG SHOWS NO CLINICAL BENEFIT

 SEATTLE, Wash., Sept. 27 /PRNewswire/ -- Immunex Corp. (NASDAQ:IMNX) announced today that preliminary data analysis of a clinical trial of the soluble tumor necrosis factor receptor (TNF receptor) in sepsis patients showed the drug provided no clinical benefit. This study has been closed.
 The Phase II, 141-patient clinical study was conducted at 14 medical centers in the United States. The trial was designed to evaluate the safety and effectiveness of TNF receptor in treating patients with sepsis syndrome, a systemic inflammatory response to infection. Patients in the study were randomly assigned to receive either a placebo or TNF receptor at one of three dose levels: low (0.15 mg/kg), medium (0.45 mg/kg) or high (1.5 mg/kg). When the study was unblinded, the results showed no difference between the mortality rate of patients treated with the lowest dose of the TNF receptor and those treated with placebo. Patients treated at higher doses had worse outcomes than the placebo group. A complete analysis of the data will be performed by the company over the next two months.
 "While the results of this study are not encouraging for pursuing additional investigation of TNF receptor in sepsis, we believe the drug has therapeutic potential in other disease settings," said Steven Gillis, Ph.D., acting chairman and chief executive officer of Immunex. "We will continue clinical trials that are ongoing in the areas of rheumatoid arthritis, human immunodeficiency virus, Crohn's disease and other inflammatory diseases and conditions. In addition, we are evaluating shifting additional resources to the clinical investigation of the Interleukin-1 receptor in sepsis as well."
 Soluble receptors function by turning off specific immune responses by preventing immune system proteins called cytokines from binding to cell-surface receptors and signaling a reaction. Immunex scientists have used recombinant DNA technology to produce soluble versions of naturally occurring cytokine receptors that intercept and inactivate these proteins.
 Immunex is a biopharmaceutical company focused on the discovery, development, manufacture and marketing of products to treat cancer and autoimmune disease.
 -0- 9/27/93
 /CONTACT: Valoree Dowell or Mary McConnon, 206-587-0430, both of Immunex/
 (IMNX)


CO: Immunex Corp. ST: Washington IN: MTC SU:

IC -- SE004 -- 5782 09/27/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 27, 1993
Words:367
Previous Article:U.S DISTRICT COURT DECIDES IN FAVOR OF CISTRON IN PATENT INFRINGEMENT SUIT
Next Article:AFFYMAX SUBSIDIARY RAISES $21 MILLION
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters